Recursion Pharmaceuticals ($RXRX) has a 30% short interest and recently published positive AI-developed drug data, making it a potential candidate for a short squeeze despite dilution concerns. Jim Cramer is "max bearish" on the stock, calling it "horrendous" and "speculative," which could be a contrarian indicator for some investors.